Today: 8 June 2026
Browse Category

NYSE:ABT 20 November 2025 - 25 January 2026

Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low

Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low

Abbott shares fell 10.04% Thursday, their sharpest drop since 2002, closing Friday at $107.42. Analysts cut price targets after the company reported Q4 adjusted EPS of $1.50 and warned of weak nutrition sales for “a couple quarters.” Volume spiked to 37.1 million shares. The company expects full-year 2026 adjusted EPS of $5.55 to $5.80 and plans to close its Exact Sciences acquisition in Q2.
25 January 2026
·
Abbott stock price: ABT heads into Monday after a two-day slide on nutrition worries

Abbott stock price: ABT heads into Monday after a two-day slide on nutrition worries

Abbott shares closed at $107.42, down 1.1% after a 10% plunge Thursday, as investors reacted to weak quarterly sales and a soft 2026 outlook. Nutrition sales fell 8.9% to $1.94 billion, while medical devices rose 12.3%. CEO Robert Ford cited U.S. pediatric nutrition market-share losses and price hikes for lagging volume. Abbott’s Indian unit faces scrutiny in a codeine syrup probe but is not named as a suspect.
25 January 2026
·
Abbott stock price dips again after earnings shock as analysts trim targets

Abbott stock price dips again after earnings shock as analysts trim targets

Abbott shares fell 1.1% to $107.42 in after-hours trading Friday, extending losses after the company forecast first-quarter profit below Wall Street estimates and missed revenue targets. CEO Robert Ford cited higher manufacturing costs and weaker nutrition demand. Wells Fargo cut its price target, citing headwinds in nutrition and diagnostics. Abbott reported Q4 sales up 4.4% to $11.46 billion and raised device sales 12.3%.
24 January 2026
··
Abbott stock sank 10% on earnings — what traders watch before the bell

Abbott stock sank 10% on earnings — what traders watch before the bell

Abbott shares hovered near $109 in early premarket Friday after a 10% post-earnings drop, following a fourth-quarter revenue miss driven by weakness in nutrition and diagnostics. Nutrition sales fell 8.9% to $1.94 billion, while medical-device sales rose 12.3%. The company forecast first-quarter adjusted earnings of $1.12 to $1.18 per share and expects to close its Exact Sciences acquisition in Q2.
23 January 2026
··
Abbott stock sinks 10% after outlook misses estimates — what ABT investors watch next

Abbott stock sinks 10% after outlook misses estimates — what ABT investors watch next

Abbott shares fell about 10% to $108.61 in after-hours trading Thursday after fourth-quarter revenue missed estimates and the company issued a weaker first-quarter profit forecast. Nutrition sales dropped 8.9% to $1.94 billion, and diagnostics revenue declined 2.5%. CEO Robert Ford said nutrition growth will remain “challenged” for several quarters. Abbott expects full-year adjusted earnings of $5.55 to $5.80 per share.
22 January 2026
··
Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus

Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus

Abbott shares fell 7.4% to $111.74 after quarterly revenue missed estimates and the company issued a weaker profit forecast. Fourth-quarter sales dropped to $11.46 billion, below the $11.80 billion expected. Nutrition revenue declined 8.9%, and diagnostics fell 2.5%. The company cited lower volumes and price actions in nutrition and forecast new product launches in 2026.
22 January 2026
··
Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch

Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch

Abbott Laboratories shares rose 0.2% to $121.34 midday Wednesday, lagging broader healthcare gains ahead of Thursday’s earnings report. The company secured EU clearance for its TactiFlex Duo ablation catheter and announced a partnership with AtaCor Medical to develop an extravascular defibrillator. Investors await guidance on 2026 and updates on the $21 billion Exact Sciences acquisition.
21 January 2026
··
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
·······
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott shares closed up 0.97% at $125.78 Tuesday, holding steady after hours. Exact Sciences, which Abbott plans to acquire for up to $23 billion, disclosed accelerated executive payouts to address “golden parachute” tax rules. Investors are tracking Abbott’s Volt device rollout and a recent FDA alert on its diabetes sensors. U.S. stocks ended lower in thin holiday trading.
31 December 2025
·
Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms

Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms

Abbott Laboratories received FDA approval for its Volt Pulsed Field Ablation system to treat atrial fibrillation, entering a competitive U.S. market. The company also announced a planned $23 billion acquisition of Exact Sciences and addressed an FDA alert on certain FreeStyle Libre sensors. Abbott shares last closed in the mid-$120s before the Christmas holiday.
25 December 2025
·
Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26

Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26

Abbott Laboratories closed at $124.81 on Dec. 24, up 0.22%, and rose to $125.18 in after-hours trading on light volume. The session saw no major company headlines, with trading muted ahead of Christmas. Investors are watching the recent Volt™ PFA system clearance, a dividend increase, and the pending Exact Sciences acquisition as markets prepare to reopen Friday.
25 December 2025
·
Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories closed at $124.54, down 0.53% Tuesday, after receiving U.S. FDA approval for its Volt Pulsed Field Ablation system to treat atrial fibrillation. Shares traded near $124.20 after hours. Trading volume was muted ahead of Wednesday’s early market close. The FDA decision follows results from a 392-patient clinical trial.
24 December 2025
··
Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories shares closed at $128.06 on Tuesday, up 0.66%. Senior Vice President Eric Shroff sold 1,586 shares for about $203,000 that day, according to a Form 4 filing. The company’s market cap stands near $223 billion, with a 52-week range of $110.81 to $141.16. Investors are watching a $21 billion Exact Sciences deal and a safety correction for Libre 3 sensors.
26 November 2025
··
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences shares traded near $101 on Nov. 25, just below their all-time high, after Abbott’s $21 billion takeover offer at $105 per share. The stock surged 45% in a week, with Wall Street downgrading to “Hold” as merger-arb funds entered. Closing is expected in Q2 2026, pending approvals. Shareholder lawyers have begun reviewing the deal.
25 November 2025
··
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences shares traded near $101, just below Abbott’s $105-per-share cash offer, as analysts adjusted ratings and a law firm launched a fairness probe into the deal. The stock hovered near its 52-week high, up almost 80% year-to-date. UBS and Jefferies set new $105 targets, while Benchmark and Leerink downgraded the stock. Market cap stood at about $19.1 billion.
24 November 2025
··
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories announced a deal to acquire Exact Sciences for $105 per share in cash, valuing the company at about $21 billion in equity and $23 billion including debt. The boards of both companies approved the transaction, which is expected to close in Q2 2026 pending regulatory and shareholder approval. Exact Sciences stock surged, while Abbott shares dipped slightly.
20 November 2025
··
1 2 3

Stock Market Today

  • Shenzhen Creality 3D Technology Shares Rise 6.2%; Valuation Viewed as Overpriced
    June 8, 2026, 3:10 PM EDT. Shenzhen Creality 3D Technology (SEHK:3388) shares jumped 6.2% to HK$22.2, reversing a 2.6% year-to-date decline. Despite 36.7% revenue growth to CN¥3,127.04 million, the company reported a net loss of CN¥182.561 million, with a negative 16.94% return on equity. Valued around HK$10.36 billion, the firm's price-to-sales ratio (P/S) stands at 2.9x, notably above the Asian tech sector average of 1.7x, suggesting investors price in growth despite losses. Limited valuation crosschecks leave the high P/S as a key indicator. Heavy overseas market reliance and ongoing losses may challenge the premium valuation. Investors are urged to consider alternative robotics and automation stocks with lower multiples.

Latest articles

Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

8 June 2026
Nu Holdings shares slid 3.1% to $11.60 as investors weighed CFO transition risks and rising credit costs, erasing last week’s 4.1% buyback-driven bounce; BofA downgraded the stock to Underperform with a $10 target, citing uncertainty from Lago’s exit, while Nu’s $1B buyback failed to stem a 10.7% weekly drop and 30.7% year-to-date decline, leaving shares just above their 52-week low.
Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

8 June 2026
Inno Holdings shares soared twentyfold to $20.97 after announcing a $3 million AI sales agent deal for its used mobile phone business, but investor risks remain with a recent $60 million at-the-market stock program and ongoing going-concern warnings in filings, as the project is still in early development and not yet commercially launched.
Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

8 June 2026
Emirates slashed June A380 flights on 10 major routes as soaring fuel costs and Middle East airspace disruption forced airlines to cut capacity, prompting IATA to halve its 2026 global profit forecast to $23 billion from $41 billion, with industry-wide seat reductions and rising fares expected as carriers struggle to absorb shocks during peak travel.
Wall Street Watches Microsoft’s $37 Billion AI Bet

Wall Street Watches Microsoft’s $37 Billion AI Bet

8 June 2026
Microsoft shares fell 1.5% to $410.30 as investors weighed bullish analyst calls and NHS England’s Copilot rollout against concerns that surging AI revenue—now at a $37 billion run rate—may not outpace rising costs and margin pressure from heavy infrastructure investment.
Cerebras shares jump as Wall Street eyes AI chipmaker’s Nvidia bid

Cerebras shares jump as Wall Street eyes AI chipmaker’s Nvidia bid

8 June 2026
Cerebras shares soared about 20% to $241.44 after Wall Street analysts initiated coverage post-IPO, citing rapid demand for fast AI inference and partnerships with OpenAI and AWS; Needham set a $300 price target, while the average analyst forecast reached $295, as chip stocks broadly rebounded and the PHLX Semiconductor Index jumped over 6%.
Go toTop